Compare · MRNA vs RXRX
MRNA vs RXRX
Side-by-side comparison of Moderna Inc. (MRNA) and Recursion Pharmaceuticals Inc. (RXRX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MRNA and RXRX operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- MRNA is the larger of the two at $63.41B, about 33.3x RXRX ($1.91B).
- Over the past year, MRNA is up 541.9% and RXRX is down 26.3% - MRNA leads by 568.2 points.
- MRNA has been more active in the news (10 items in the past 4 weeks vs 9 for RXRX).
- MRNA has more recent analyst coverage (25 ratings vs 10 for RXRX).
- Company
- Moderna Inc.
- Recursion Pharmaceuticals Inc.
- Price
- $158.81+14.40%
- $3.56+9.71%
- Market cap
- $63.41B
- $1.91B
- 1M return
- +185.74%
- +18.27%
- 1Y return
- +541.94%
- -26.29%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2018
- 2021
- News (4w)
- 10
- 9
- Recent ratings
- 25
- 10
Moderna Inc.
Moderna, Inc., a biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases. As of March 9, 2021, the company had 13 programs in clinical trials and a total of 24 development programs in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted and cell surface therapeutics, and systemic intracellular therapeutics. The company has strategic alliances with AstraZeneca PLC, Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, the Biomedical Advanced Research and Development Authority, the Defense Advanced Research Projects Agency, the National Institute of Allergy and Infectious Diseases, the National Institutes of Health, the Coalition for Epidemic Preparedness Innovations, and Bill & Melinda Gates Foundation. Moderna, Inc. also has collaborations with Lonza Ltd. for the manufacture of COVID-19 vaccine; and Catalent Inc., Laboratorios Farmacéuticos Rovi, S.A., Recipharm, and Lonza Group for fill-finish manufacturing of its COVID-19 vaccine candidate, as well as Aldevron, LLC for supporting COVID-19 vaccine and additional programs in company's clinical development pipeline. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Recursion Pharmaceuticals Inc.
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. It has four clinical-stage drug candidates focused on rare, monogenic diseases; and 33 additional programs in various stages of preclinical development. Recursion Pharmaceuticals, Inc. has strategic agreements with Bayer; Ohio State Innovation Foundation; Chromaderm, Inc.; and Takeda Pharmaceutical Company Limited. The company was founded in 2013 and is based in Salt Lake City, Utah.
Latest MRNA
- Moderna upgraded by Wolfe Research
- Moderna upgraded by BofA Securities
- Moderna upgraded by William Blair
- Merck and Moderna Announce Phase 3 INTerpath-001 Trial of Intismeran Autogene Plus KEYTRUDA® Met Endpoints of Recurrence-Free Survival (RFS) and Distant Metastasis-Free Survival (DMFS) in Patients With Completely Resected Stage IIB-IV Melanoma
- SEC Form SCHEDULE 13G filed by Moderna Inc.
- Chief Executive Officer Bancel Stephane exercised 751,715 shares at a strike of $19.15 and sold $28,715,011 worth of shares (499,246 units at $57.52) as part of a pre-agreed trading plan, increasing direct ownership by 4% to 6,440,260 units (SEC Form 4) to satisfy withholding tax
- Amendment: SEC Form SCHEDULE 13G/A filed by Moderna Inc.
- Moderna Receives U.S. FDA Approval for Influenza Vaccine mFLUSIVA
- SEC Form 144 filed by Moderna Inc.
- Moderna Announces Initiation of Phase 1 Clinical Trial of mRNA-1469, Moderna's Investigational Vaccine Against Bundibugyo Ebolavirus
Latest RXRX
- CEO and President Khan Najat covered exercise/tax liability with 80,498 shares, decreasing direct ownership by 4% to 2,095,298 units (SEC Form 4) (withholding tax)
- Chief Financial Officer Taylor Ben R covered exercise/tax liability with 25,018 shares, decreasing direct ownership by 2% to 1,076,858 units (SEC Form 4) (for withholding tax)
- Chief Scientific Officer Hallett David covered exercise/tax liability with 26,657 shares, decreasing direct ownership by 2% to 1,043,837 units (SEC Form 4) to cover taxes
- SEC Form SCHEDULE 13G filed by Recursion Pharmaceuticals Inc.
- Director Borgeson Blake sold $97,500 worth of shares (30,000 units at $3.25) as part of a pre-agreed trading plan, decreasing direct ownership by 0.48% to 6,188,287 units (SEC Form 4)
- SEC Form 10-Q filed by Recursion Pharmaceuticals Inc.
- Recursion Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- Recursion Reports Second Quarter Financial Results; Genentech Options First Neuroscience Target into Early Discovery Program
- Recursion to Participate in Upcoming Investor Conferences
- Recursion Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules